All In Biotech

Drug Trial Radar · NCT05611229

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden: An Observational Study

Last checked: Nov 20, 2026Latest source record: Apr 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,975

Actual

Start

Jun 16, 2020

Primary completion

Dec 3, 2021

Study completion Dec 3, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 9, 2022

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was an observational study utilizing electronic health record (EHR)-derived data collected retrospectively during routine care of real-world patients with advanced melanoma from NOBLE (Novartis Braf+ meLanoma patients ObsErvational) dataset.

Conditions

  • Metastatic Melanoma

Interventions

  • NivolumabDrug

    Nivolumab

  • PembrolizumabDrug

    Pembrolizumab

  • Dabrafenib+TrametinibCombination product

    Dabrafenib+Trametinib

  • Ipilimumab+NivolumabCombination product

    Ipilimumab+Nivolumab

  • Vemurafenib+CobimetinibCombination product

    Vemurafenib+Cobimetinib

  • Encorafenib+BinimetinibCombination product

    Encorafenib+Binimetinib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients receiving TT and IO therapy in the first-, and second-lineTime frame: throughout the study period, approximately 6 years (i.e., 01 January 2014 to 30 August 2020 for population 1 and 01 January 2014 to 31 May 2020 for population 2
  2. Proportion of patients switching from TT 1L therapy to IO 2L therapyTime frame: throughout the study period, approximately 6 years (i.e., 01 January 2014 to 30 August 2020 for population 1 and 01 January 2014 to 31 May 2020 for population 2
  3. Proportion of patients switching from IO 1L therapy to TT 2L therapyTime frame: throughout the study period, approximately 6 years (i.e., 01 January 2014 to 30 August 2020 for population 1 and 01 January 2014 to 31 May 2020 for population 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.